AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD
AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029.
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that patients in a mid-stage trial of its experimental depression treatment BPL-003 showed improvement within two days of a single dose, with effects lasting up to 12 weeks. The Phase 2a study found that 66.7% of participants achieved a clinically significant reduction in symptoms by Day 2.
AtaiBeckley awarded ‘Buy' rating in initial coverage from Deutsche Bank analysts
Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating and setting a price target of $12, implying potential upside of around 320% from current levels. In a note to clients, analysts highlighted the company's position in the emerging field of psychedelic medicine for mental health.
AtaiBeckley added to major US indices, increasing reach among passive investors
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benchmark indices, a move that is expected to increase its visibility among institutional investors and trigger buying from passive investment funds. The clinical-stage biotechnology company announced that it joined the S&P Total Market Index, the S&P Completion Index and CRSP US benchmark indices, effective March 23, 2026.
AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish
AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. BPL-003 posted encouraging depression data and has the FDA's Breakthrough Therapy Designation. We also know BPL-003 is expected to enter Phase 3 in Q2 2026. VLS-01 and EMP-01 add pipeline depth.
AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has reported its fourth quarter and full-year 2025 financial results, highlighting progress across several clinical programs targeting mental health disorders and outlining upcoming milestones for its pipeline. The clinical-stage biotechnology company said it remains on track to initiate a Phase 3 pivotal program for BPL-003, its mebufotenin benzoate nasal spray for treatment-resistant depression (TRD), in the second quarter of 2026.
AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing
The FDA has supported the Phase 3 design for BPL-003, an intranasal psychedelic-derived therapy for treatment-resistant depression AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC), a clinical-stage biotechnology company focused on mental health treatments, has received backing from US regulators to advance its BPL-003 drug candidate into Phase 3 clinical trials for treatment-resistant depression, a condition affecting millions of patients for whom standard antidepressants have failed. The company said a formal end-of-phase 2 meeting with the Food and Drug Administration (FDA) concluded successfully, with the regulator indicating support for its proposed pivotal trial programme and providing constructive feedback on study design, safety database requirements and other key components.
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has reported positive topline results from an exploratory Phase 2a trial evaluating its oral R-MDMA candidate, EMP-01, in adults with social anxiety disorder (SAD), with the study meeting its primary safety objective and showing encouraging efficacy signals. The clinical-stage biotechnology company said the randomized, double-blind, placebo-controlled study enrolled 71 adults with moderate-to-severe SAD across seven sites in the United Kingdom.
AtaiBeckley names Michael Faerm as finance chief
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25 years of experience spanning life sciences firms, equity research and investment banking.
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.
